Sunday, 23 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com

OXURION Stock Went Up By Over 25% At Session Start On Wednesday

Loading stream...

(VIANEWS) - Shares of OXURION (BEL 20: OXUR.BR) rose by a staggering 25.71% to 0.02 € at 10:25 EST on Wednesday, after four consecutive sessions in a row of losses. BEL 20 is jumping 1.23% to 3,920.71 €, after three sequential sessions in a row of losses. This seems, as yet, an all-around bullish trend trading session today.

OXURION's last close was 0.02 €, 99.2% under its 52-week high of 1.95 €.

About OXURION

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Earnings Per Share

As for profitability, OXURION has a trailing twelve months EPS of -0.732 €.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -694.15%.

Volume

Today's last reported volume for OXURION is 11010595 which is 57.63% below its average volume of 25989200.

Moving Average

OXURION's value is above its 50-day moving average of 0.02 € and way below its 200-day moving average of 0.24 €.

Volatility

OXURION's last week, last month's, and last quarter's current intraday variation average was a negative 5.71%, a negative 2.85%, and a positive 12.84%.

OXURION's highest amplitude of average volatility was 5.71% (last week), 7.00% (last month), and 12.84% (last quarter).

Yearly Top and Bottom Value

OXURION's stock is valued at 0.02 € at 10:25 EST, way under its 52-week high of 1.95 € and way above its 52-week low of 0.01 €.

More news about OXURION (OXUR.BR).